Recent studies also show that ANRIL can act as an oncogenic ceRNA to facilitate tumor progression via miRNA regulation, including mechanisms involving let-7a (215) and miR-125a (216) in nasopharyngeal carcinoma, miR-99a (217) and miR-449a (218) in gastric cancer, miR-34a (219) in glioma, miR-122-5p (220), miR-191 (221), miR-144 (222), and miR-199a-5p (223) in hepatocellular carcinoma, miR-186 (224) in cervical cancer, let-7a in prostate cancer (225) and colorectal cancer (226), miR-125a-5p (227) in endometrial carcinoma, and miR-199a (228) in breast cancer. Here, CDKN2B-AS1 is linked to neoplasm.